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7Summary 
The existence of cancer stem cells (CSCs) in solid cancers is still a controversial issue. 
Several markers were successfully used to enrich for cells with stem cell-like 
properties in oral squamous cell carcinoma (OSCC). Among these, ALDH1 was 
reported in both OSCC and several other human cancers. The aim of this study was to 
investigate the pattern of expression of several CSC-related markers including ALDH1 
and the normal oral keratinocyte stem cell marker p75NTR relative to each other in 
patient samples and OSCC-derived cells, and the potential of p75NTR to identify and 
isolate CSCs in OSCC. 
To simultaneously detect several CSC-related markers in patient samples, a multiple 
IHC protocol engaging three un-conjugated monoclonal primary antibodies from the 
same Ig subclass was first developed, based on previously reported protocols. 
Compared to other methods, stripping of the preceding reaction by microwave heating, 
combined with additional suppression of enzyme activity, has enabled specific 
detection of all three reactions by using the same detection system, with no detectable 
cross reactivity. Archival formalin-fixed paraffin embedded tissues from OSCC 
(n=177), oral dysplasia (OD, n=10), and normal human oral mucosa from healthy 
donors (NHOM, n=31) have been subjected to the developed multiple IHC protocol, 
while keratinocytes derived from OSCC, OD and NHOM were subjected to multiple 
fluorescent activated cell sorting (FACS). The findings of the two approaches showed 
a wider range of variability in the level of expression and localization of the CSC-
related markers in OSCC and OD as compared to NHOM. In addition, the data also 
indicated a functional difference between different cellular phenotypes positive for 
either p75NTR or ALDH1A1.  Firstly, higher proliferation (Ki67) was observed in 
p75NTR+ cells in comparison to ALDH1+ or p75NTR+ALDH1+ cells. Secondly, the 
frequency of p75NTR+ cells was higher in OSCCs of small size (T1 & T2) and 
OSCCs with poor to moderate differentiation grade, and correlated with poor survival 
of patients clinically deemed as of better prognosis. High frequency of ALDH1+ cells 
was found to be associated with lymph node metastasis. No statistically significant 
association was found between any of the clinical variables investigated and the 
8frequency of the co-localization of CSC-related markers. Thirdly, OSCC cells sorted 
for p75NTR and ALDH1 displayed different expression profile of several CSC-EMT 
related genes. 
OSCC-derived cells sorted for p75NTR expression were compared for stem cell 
properties using both in vivo and in vitro assays. Statistically significant higher stem 
cell properties were found for the p75NTRHigh cells than for the p75NTRLowcells in all 
assays performed. This suggested that p75NTR can be used for isolating a 
subpopulation enriched for cells with stem cell–like properties in OSCC. Nevertheless, 
the p75NTRLow subpopulation did also exhibit some stem cell features, but to a lesser 
extent. Propagation of p75NTRLow cells for several passages in culture showed that the 
expression of p75NTR could rise spontaneously. This finding was also supported by 
the similar expression of p75NTR by the xenografts generated by both subpopulations 
in NOD\SCID IL2Rǳnull mice. Similar spontaneous generation of ALDH1High cells by 
propagation of ALDH1Low cells was observed, although with a different kinetic.  
Taken together, the data from this study showed high inter-patient variability in the 
expression of the CSC markers investigated, and high intra-tumor heterogeneity of the 
CSC subpopulation. The results presented here suggest also that some OSCC might 
have several distinct CSC phenotypes, each with impact on different clinical aspects, 
while other OSCC might completely lack a hierarchical organization. De novo
generation of p75NTRHigh or ALDH1High cells from their negative counterparts might 
indicate the existence of a dynamic equilibrium between cancer cells with different 
degrees of differentiation. 
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1. Background 
1.1 Oral epithelium: from normal homeostasis to carcinoma 
1.1.1 Histology and tissue architecture of normal human oral mucosa 
Oral mucosa is the moist lining of the oral cavity that is continuous with the skin at the 
lips, and the gut lining at the larynx. Like the other mucous membranes in the human 
body, the oral mucosa is composed of stratified squamous epithelium, and underlying 
connective tissue. The epithelial component is composed of different layers (strata) of 
keratinocytes: basal cell layer/ stratum basale, prickle cell layer/startum spinosum, 
granular cell layer/stratum granulosum (present only in the hard palate) and superficial 
cell layer/stratum superficiale (Figure 1). The connective tissue component is 
composed of lamina propria and submucosa. The lamina propria indents the 
epithelium in a form of projections, known as connective tissue papilla, to provide 
blood and nerve supply to the adjacent avascular structure (1).  
Figure 1: Schematic drawing illustrating different layers of the oral epithelium (A). Source: Servier   
Medical Art, http://www.servier.com/Powerpoint-image-bank.  
               Section from normal human buccal mucosa stained with H&E; own photo (B). 
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Oral mucosa is classified into three main categories: lining mucosa which is found 
around mobile structures, and has connective tissue rich in elastin; masticatory mucosa 
which covers the attached gingiva and hard palate, it is a rigid structure that is bound 
to the underlying bone by a dense connective tissue; and specialized mucosa that 
contains specialized mucosal structures like the taste buds present in the dorsum of the 
tongue (1). 
1.1.2 Homeostasis of the normal human oral epithelium  
In all multicellular organisms, the number of cells is maintained through the finely 
regulated balance between cell division, differentiation and programmed cell death 
(apoptosis) known as homeostasis (1, 2). Keratinocytes of the oral mucosa (NOKs) 
follow a distinct program in which they stop dividing, terminally differentiate, and 
shed off at the surface. The process involves acquiring characteristics necessary to the 
desired function, and partial activation of the apoptotic machinery, through sequential 
expression of different genes (3, 4). Keratinocytes are produced in the basal and 
parabasal cell layers by division of the stem cells and their direct progeny, the transit 
amplifying cells (TAs) (1). Stem cells of the oral mucosa reside within the basal layer 
in clusters that are located at the tips of the connective tissue papilla and the deep rete 
ridges, and have a slow cycling rate (5), while their actively cycling progeny (TA) 
migrates laterally and upwards, forming a clone-like pattern, and are cycling more 
rapidly (6). Differentiation process of the keratinocytes starts by breaking the 
attachment to the basal lamina (basement membrane), an important trigger of the 
maturation process. Keratinocytes are pushed up by the pressure generated by 
proliferation of the cells in the layers underneath (Figure 2), leading to the 
stratification of the tissue (1).  
During their migration to the surface, oral keratinocytes follow one of two major 
scenarios. First scenario occurs at the surface of masticatory mucosae, where 
keratinocytes lose their nuclei and cytoplasmic organelles, and become filled with 
keratin forming a cornified layer (3), that is suitable for its desired function as a 
resilient barrier and a frictional withstander. In the second scenario terminal 
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differentiation does not include a cornification process; instead, it results in the more 
elastic barrier of the lining mucosae. Moreover, special forms of terminal 
differentiation are site specific, and result in the formation of epithelial appendages 
like the filiform papillae at the dorsum of the tongue. In all types of mucosa, the 
surface layer is regularly shed, and replaced by successors from the underlying layers 
(1).  
Figure 2: Schematic drawing illustrating upwards migration of differentiating keratinocytes, the 
localization of stem cells and transit amplifying cells; Source: Modified from: ALBERTS B, 
JOHNSON A, LEWIS J et al. Molecular Biology of The Cell. Garland Science: New York, 
2008; 1600. 
1.1.3 Stem cells 
Stem cells are important players in tissue homeostasis, and are very unique in their 
ability of self-renewal and differentiation to various tissue specific lineages (4). The 
microenvironment of stem cells controls the balance between their self-renewal and 
differentiation capacities, and subsequently homeostasis of the organ is achieved. They 
are slow cyclers that normally remain dormant until they receive a stimulating signal 
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when their activity is needed, as during wound healing (4). When activated, stem cells 
have unlimited replicative potential and may divide asymmetrically to give rise to one 
stem cell that remains quiescent in the stem cell niche until another stimulating signal 
is received, and thus the self-renewal, while the other offspring being committed to 
differentiation (Figure 3). Stem cells may also divide in a symmetrical pattern either to 
reproduce two daughter cells both of which enter differentiation pathways, or two 
daughter stem cells, so as to maintain the stem cell pool like in situations of tissue loss 
by wounding. In comparison, transient amplifying cells are actively proliferative, but 
are destined for differentiation later during their life time (4). This hierarchical 
organization was shown in normal human oral mucosa, and has drawn attention as a 
possible cell source for tissue engineering and reconstructions (5).  
Figure 3: Asymmetrical division of stem cells resulting in one daughter stem cell and a committed 
transit amplifying cell. Source: ALBERTS B, JOHNSON A, LEWIS J et al. Molecular Biology 
of The Cell. Garland Science: New York, 2008; 1600.
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1.1.4 The role of the microenvironment 
As surface barrier, the epithelium has to adapt to tough circumstances, like wounding 
or continuous friction, and keep the surface properly covered while homeostasis is still 
maintained. This is achieved by modulating the proliferation rate of both TAs and stem 
cells, the fate of the stem cell progeny and the time for TAs to enter and complete the 
differentiation program. These processes are modulated, according to the needs, by a 
multitude of signalling molecules mediating the interaction of keratinocytes with each 
other, with other types of cells in their surroundings and with extracellular matrix 
components. For example, contact with the basal lamina was found to keep 
keratinocytes at the basal layer undifferentiated via integrins signalling, and basal 
keratinocytes grown in suspension stop dividing and start to differentiate (4). Both the 
stem cells and TAs respond to stimuli in their microenviroment to meet the tissue 
needs. As already mentioned, TAs start their differentiation program by getting 
unleashed from the basal lamina, and migrate up to the parabasal compartment. On the 
other hand, the microenvironment of the stem cells, often called the stem cell niche, is 
apparently essential for them to remain in an undifferentiated state (4). 
1.1.5 Molecular control of stemness and differentiation 
During differentiation, progenitor cells become committed to a specific lineage, and 
expression of genes required for differentiation into other lineages become restricted. 
These restrictions become inheritable through epigenetic modifications to the DNA 
that serve as cellular memory of lineage commitment (7). On the other hand, stem cells 
have gene expression potential that enables them to differentiate into various tissue 
lineages (7), an ability referred to as cell potency. The self-renewal capacity of stem 
cells renders them permanent residents of the tissue, by maintaining at least a daughter 
cell in an undifferentiated state. Substantial knowledge of the regulatory circuit is so 
far lacking, but several transcription factors, including Oct4A, SOX2, c-myc and Klf4 
and NANOG, have been found to promote both self-renewal and pluripotency in 
embryonic stem cells (8, 9). In addition, other molecular mechanisms have been 
described to be involved in maintain the hierarchy of the tissue.  
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Polycomb group proteins (PcG) 
Members of this group repress the expression of some genes by exerting epigenetic 
modifications in the targeted genes, which have to be reversed upon differentiation (2, 
7). They have been named “the guardians of stemness” because many of their targeted 
genes were found to promote differentiation (2). However, human DNA mapping 
revealed that some of the targeted genes carry both repressive and activating PcG 
mark, comprising a bivalent domain (7). Accordingly, binding to the bivalent domain 
comprises a cell fate decision, and PcG contributes to stem cell pluripotency by 
postponing lineage commitment (7). In addition, the PcG members BMI1 was found to 
be essential in self-renewal of mammary and hematopoietic stem cells (10, 11). BMI1 
also functions as a transcriptional repressor of two tumor suppressor genes, P16ink4a 
and P14Arf. The first is a cyclin-dependent kinase inhibitor while the later promotes 
apoptosis and cell cycle arrest (4, 12). 
Wingless (Wnt) signalling Pathway 
Tcf/LEF family of transcription factors regulates, among others, several genes 
involved in the cell cycle control (e.g: c-myc, cyclin D and adhesion molecules from 
the EPH family). B-catenin, an important component of the adherence junction, is 
made available and accumulates in the nucleus when Wnt pathway is activated (13). 
B-catenin serves as co-activator of Tcf/LEF family of transcription factors. A 
degradation complex composed of proteins, and located in the cytoplasm, can 
molecularly flag B-catenin for degradation by the proteasome (Figure 4A). This 
degradation complex includes axin, APC, GSK3B and CKI. Wnt signaling pathway 
disrupts the degradation complex mentioned above by recruiting the axin by one of the 
pathway mediators (phosphorylated LRP, Figure 4B). Research have shown that Wnt 
pathway is required for self-renewal of neural (14, 15), intestinal and haematopoetic 
(16) stem cells.  
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Figure 4: Wnt signaling pathway. Recruitment of ȕ-catenin by the cytoplasmic degradation complex 
(A), ȕ-catenin made available by disruption of the degradation complex (B). Source: 
ALBERTS B, JOHNSON A, LEWIS J et al. Molecular Biology of The Cell. Garland Science: 
New York, 2008; 1600. 
Hedgehog pathway (Hh) 
Hedgehog pathway is another pathway that seems to be involved in self-renewal (2, 
10). The signal transduction is mediated by two transmembrane molecules, Patched 
and Smoothened. In the absence of the Hh ligands (Figure 5A), patch inhibits 
Smoothened and suppresses the pathway. The signal is transduced upon relieve of this 
inhibition by binding of patched to the ligand (Figure 5B). Although the rest of the 
signaling cascade has not been fully elucidated, it involves the release of the zinc 
finger transcription factor Gli from a protein complex to facilitate its translocation to 
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the nucleus (2, 10). The isoform Gli2 was found to promote self-renewal of mammary 
progenitor cells by modulating the expression of BMI-1 (10).  
Figure 5: Inhibition of Smoothened by Patched in the absence of Hodgehog signal (A), 
Phosphorylation of Smoothend and internalization of Patches and activation of the pathway 
upon ligand binding. Source: ALBERTS B, JOHNSON A, LEWIS J et al. Molecular Biology of 
The Cell. Garland Science: New York, 2008; 1600. 
Notch pathway  
Notch pathway plays an essential role in cell fate decision in nearly all developing 
tissues (4, 17), and was found involved in both stem cell fate and maintenance in 
embryonic (18) and adult (19, 20) stem cells. The pathway is triggered by binding of 
any of the Delta-Serrate-LAG2 (DSL) ligands from one cell, to the transmembrane 
receptor notch in a neighboring one. This binding results in cleavage of notch 
cytoplasmic tail, and subsequent translocation to the nucleus (Figure 6). The cleaved 
cytoplasmic tail participates in core transcriptional complexes, and thus aids in 
transcription of targeted genes (4, 17). The genes regulated by notch signaling were 
found to promote variable cellular processes during development, depending on the 
tissue and biological circumstances (4, 17). The pathway plays a role in limiting the 
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number of stem cells, by inducing neighbor cells to become TAs (4). Recently, a role 
of Notch signaling in self-renewal was also proven in roundworms (21). 
Figure 6: Notch signaling pathway. Source: ALBERTS B, JOHNSON A, LEWIS J et al. Molecular 
Biology of The Cell. Garland Science: New York, 2008; 1600. 
21
1.1.6 Oral keratinocyte stem cells (OKSC) 
Oral keratinocytes stem cells are, so far, difficult to purify. Nevertheless, several 
markers have been found to identify subpopulations with stem cell-like properties. 
And therefore are considered adequate only to enrich for keratinocyte stem cells.
Į6ȕ4 integrin+ CD71-  
Integrins are a family of transmembrane receptors that function as cell adhesion 
molecules. By binding to laminin-5 in the basement membrane, Į6ȕ4 integrin was 
found to be fundamental for hemidesmosome assembly, and its expression was found 
to be a characteristic of the basal layer keratinocytes in normal epithelium (22). Thus, 
it was theorized that Į6ȕ4 integrin can be used to isolate both the slow cycling stem 
cells and the rapidly proliferating early TAs. These observations were exploited to 
enrich for OKSCs, and cells positive for Į6ȕ4 integrin but negative for the proliferation 
marker CD71 were found to display more stem cell properties as compared to Į6ȕ4
integrin+ CD71+ cells (23).  
CD44High
CD44 is a transmembrane glycoprotein whose functions involve cell adhesion, 
motility, proliferation and survival (24). Normal human oral keratinocytes expressing 
high levels of CD44 were shown to display stem cell-like properties, including high 
proliferative capacity and resistance to apoptosis (25). 
p75NTR 
The low affinity nerve growth factor receptor p75NTR was found to identify clusters 
of slow cycling keratinocytes in the basal layer of oral epithelium (5). In vitro analysis 
of p75NTR+ oral keratinocytes indicated that this subpopulation is enriched in stem 
cells, and suggested a role of this molecule in maintaining cell survival (5, 26).  
P75NTR is a transmembrane receptor composed of extracellular, transmembrane and 
intracellular domains, and has been structurally affiliated to the tumor necrosis factor 
receptor superfamily (27).  Depending of the type of cell and biological context, 
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p75NTR serves a wide spectrum of functions including survival, proliferation, 
apoptosis and differentiation.  Functions of p75NTR was found to be modulated by its 
own level of expression, post-translational modifications, dimerization, ligand binding 
and engagement with co-receptors as well as intracellular partners (28). Interestingly, 
p75NTR was found to be expressed by mouse embryonic (29), mammalian neural 
crest (30, 31) and human esophageal keratinocyte (32) stem cells, in addition to 
several other extra neuronal stem/progenitor cells [reviewed by Tomellini et. al (28) 
and references therein].  
1.1.7 Carcinogenesis and disruption of homeostasis 
Carcinogenesis is a multistep process that results from accumulation of unrepaired 
DNA alterations that are passed on to the next generation of cells. Therefore, cancer is 
considered a genetic disease at the cell level (2). Over time, this may lead to genetic 
instability, and more mutations are likely to occur, including mutations in the tumor 
suppressor and/or proto-oncogenes (33). The accumulating mutations in a cell result in 
acquiring certain biological capabilities referred to as “the hallmarks of cancer” (34). 
Among others, cancer cells are capable of proliferating unlimitedly, and independently 
of exogenous growth signals. Moreover, they are capable of escaping growth 
inhibitory signals and destruction by the immune system and apoptosis (34). A logical 
consequence of such behavior is aberration of tissue homeostasis, and formation of a 
tissue mass whose growth exceeds that of a normal one, a tumor (33). Subsequently, 
there is a rising need, within a tumor, for oxygen and nutrients. Cancer cells evade this 
scarcity by inducing formation of new blood vessels (angiogenesis), and by local 
invasion and metastasis which are also among the hallmarks of cancer (34).  
1.1.8 Oral Squamous Cell Carcinoma (OSCC) 
In general, sites of oral cancer include the mucosae of the lips, cheeks, tongue, 
gingivae, palate and the floor of the mouth. In 2008, International Agency for 
Research on Cancer estimated 400000 new cases of oral and pharyngeal cancers per 
year (35). The incidence is highly variably in different geographical regions, and oral 
cancer was ranked as the sixth incident cancer in males in the developing 
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countries(35). In 2012, 300000 cases of oral cancer were reported worldwide (36). The 
most common type of oral cancer is OSCC, accounting for 90% of the cases (35, 37, 
38). Risk factors of OSCC include, tobacco and alcohol use, infection with human 
papilloma virus or Candida Albicans, poor immunity, chronic irritation of the lip by 
exposure to UV light or the tongue by local friction with a sharp object (35, 39).  
Like many other malignancies, OSCC is considered to be a multi-step disease, and 
progression from premalignant (dysplastic) lesions is a common finding (Figure 7). A 
major biological event in the progression of OSCC is metastasis to the regional lymph 
nodes (39). Routinely used treatment modalities are surgical resection of the primary 
tumor and cervical lymph nodes, radiotherapy and the combination of both, depending 
on the anatomic site and tumor stage (35, 39). Surgical resection often results in 
impairment of speech, nutrition and appearance depending on the extent of resection. 
Accordingly, health-related quality of life was found to be proportional to preoperative 
functional impairment caused by the tumor (40). Additional use of conventional 
chemotherapy yielded conflicting results, with the prognosis remaining poor in many 
reports (39, 41), and resistance developing during the course of the disease (41). 
Cetuximab, an antibody against epithelial growth factor receptor (EGFR), was found 
beneficial when given in combination with radiotherapy (42). Nevertheless, the 
survival rates remained virtually the same since 1980s, reflecting no major progress in 
the treatment (35, 43). Prognosis is influenced by the clinical stage and the histologic 
subtype. The overall survival rate for OSCC is below 50%, and occurrence of lymph 
nodes metastasis was found to result in a dramatic decrease in the survival rates, while 
early stage tumors were found to have a better survival rate (44).  Histologic grading 
based on the differentiation level was found to be relevant to the patient prognosis and 
patients with highly differentiated tumors were reported to have better prognosis (39). 
Other prognostic indicators include, histological pattern of invasion (45), status of 
surgical margins (46), patient age, gender, general health and mental status (39).  High 
rates of loco-regional recurrence of OSCC have been reported (47), and the poor 
survival rates and treatment failure have been attributed to that (48).  
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Figure 7: Hematoxylin and Eosin stained sections of:  NHOM (A), Hyperplastic oral epithelium (B), 
Oral dysplasia (C), Invasive OSCC (D), own photos. 
1.2 Heterogeneity of cancer 
A cancer cell population is composed of genotypically, phenotypically and 
functionally different mixture of cells (2). New phenotypes that are resistant to cancer 
therapy are arising as the tumor grows, even with the use of some of the most 
successful molecular targeted modern drugs. The advancement in molecular biology 
has led to the discovery of a wide range of molecular targets for second generation 
drugs that can be used when resistance to the drugs in hand develops (2). The 
commencing discoveries in this field resulted in improvement of survival of patients 
with many types of cancer in Europe. However, the combined survival index of 
patients with all types of cancer is still below 50% and 60% for men and women 
respectively (43). Improving the survival rates, and the quality of life of cancer 
patients, require thorough understanding of the mechanisms involved in the 
heterogeneity of cancer cells.  
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Crosstalk between the tumor cells and their non-neoplastic surroundings was 
implicated in creating different niches within the tumor bulk, and amended neoplastic 
phenotypes that can better serve the progression of the disease are continuously 
emerging in response to the ever changing microenvironment (49). Nevertheless, the 
intrinsic mechanism by which the tumor cells give rise to tumor heterogeneity is still 
controversial, and models proposed are the clonal evolution model (33), the cancer 
stem cell model (2), and more recently, co-existence of the two models within the 
same tumor was suggested (50).   
1.2.1 The clonal evolution (Stochastic) model 
This model proposes that the first genetic changes in the carcinogenesis process are 
passed unrepaired from the parent cell to its entire progeny, which would further 
expand when the proliferation process gets out of control. Later on, further genetic 
changes would take place due to the genetic instability, resulting in further 
phenotypical differences that are inherited to the expanding generations of cells (33, 
51). This model have been viewed as a Darwinian evolution, the cancer cells are 
obeying ‘natural order’, and the accumulating genetic changes would lead to 
adaptation to the microenvironment and selection of the fittest (2, 51). Tumor 
heterogeneity is, therefore, the result of the continuous stochastic emergence and 
expansion of new phenotypes that can better survive environmental changes. 
1.2.2 The cancer stem cell (CSC) model 
A cancer stem cell is defined as “a cell within a tumor that possesses the capacity to 
self-renew and to cause the heterogeneous lineages of cancer cells that comprise the 
tumor” (52). The role of stem cells in carcinogenesis was hypothesized during the 
1800s, when the resemblance between teratocarcinomas and the developing fetus was 
thought to be due to activation of rudimentary embryonic rests (53). However, the 
technology available at that time was not sufficient to establish a compelling proof of 
these hypotheses. It was the 1990s when the cancer stem cell model was 
experimentally proven for acute myeloid leukemia (AML) (54, 55). This discovery has 
led to extensive research to investigate the existence and characteristics of CSCs in 
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many solid tumors such as breast (56), colon (57), brain (58) prostate (59), lung (60) , 
liver (61), and melanoma (62) .                                                                                                  
This model proposes the existence of a small subpopulation of cancer cells possessing 
stem cell properties. This subpopulation is also referred to as the stem-like cancer cells 
(CSCs), the tumor initiating cells, or the tumorigenic cells (52). Comparable to tissue 
specific normal stem cells, this subpopulation is thought to be rare, enter the cell cycle 
infrequently, have the ability to self-renew, and to differentiate into heterogeneous 
phenotypes. Although the model does not address the cell of origin, it views a cancer 
cells population as an organ composed of a hierarchy of cells with different 
proliferation, differentiation, and more importantly, tumor initiation abilities. 
Accordingly, tumor heterogeneity is attributed to the continuing differentiation of 
CSCs through epigenetic modifications (52, 63, 64).
Origin of CSCs 
The origin of CSCs is a controversial matter and several proposals have been adopted 
(65). In the first place, enrichment of CSCs in AML was based on the same markers 
used to enrich for normal hematopoietic stem cells (54, 55). This has led to the first 
proposal that leukemic stem cells result from transformed normal counterparts (53, 
63). This proposal is supported by the postulation that the long life span of normal 
stem cells makes them more prone to accumulate mutations (2, 65). Nevertheless, 
consequent experimental work on AML revealed phenotypical differences between 
leukemic and normal hematopoietic stem cells (66). Experimental evidence has also 
showed that leukemic stem cells properties can be induced in hematopoietic progenitor 
cells only in some molecular subtypes of AML (67). Taken together, normal stem cells 
can be the origin of CSCs in some types of cancer (53).  
Another suggestion is that self-renewal capacity could be acquired by a differentiating 
cell if the right pathways are switched on or off by the accumulated mutations (2, 65). 
Several molecular mechanisms were found to serve in maintaining a stable genome in 
the normal stem cells in some tissues (4, 68, 69), which renders this proposal more 
conceivable in those particular tissues.  
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Fusion of hematopoietic stem cell and a differentiated somatic cell, with the resultant 
cell being able to maintain self-renewal has been suggested to explain the origin of 
CSCs (65, 70). Yet another phenomenon referred to as neosis has also been described 
in vitro and suggested as possible origin of CSCs (71, 72). Neosis is based on the 
theory that DNA damage can lead to formation of senescent giant cells that can divide 
and give rise to stem like mononuclear cells known as Raju cells (71, 72). Giant cells 
have been identified in some carcinomas but they have been described as a secondary 
reactive event of the host rather than being of neoplastic origin (73, 74). Therefore, in 
vivo evidence of neosis is so far lacking. 
CSC and invasion 
For an epithelial tumor to metastasize, cell adhesion molecules has to be broken down 
which can make the cell disassemble and change its character. Moreover, they invade 
the connective tissue stroma and may metastasize to distant locations via blood and 
lymphatics (2, 39). Escaping from their normal compartment and break down of 
intercellular binding molecules, triggers a set of intracellular events that result in 
acquiring characters of the mesenchymal component. This process is a common event 
during embryogenesis and is referred to as epithelial to mesenchymal transition 
(EMT), and the origin of the neural crest during embryogenesis is one good example 
of it (4). Metastatic breast and colorectal cancers were found to contain CSCs (75, 76). 
In both tumors CSCs were found to have undergone EMT, and the resultant phenotype 
was given the name migrating cancer stem cells (13, 77). This phenotype retains stem 
cell properties, like quiescence ability, resistance to therapy and high proliferation 
potential, in addition to being more suited to invasion and metastasis. 
CSCs and anti-cancer drug resistance 
In addition to their role in tumor growth, heterogeneity and invasion, it has been 
theorized that CSCs can survive classical therapies designed to target highly 
proliferating cells, given their slow cycling rate at equilibrium (52) and indeed 
multiple drug resistance was shown for CSC and have been considered to be an 
intrinsic ability of these cells (50, 78, 79). The presence of membrane transporters as 
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ABCG2, can aid CSCs to efflux chemotherapeutic drugs (78). Moreover, resistance to 
new molecular targeted, comparatively successful, drugs like Imatinib was found to be 
a feature of leukemic stem cells (80, 81). It has also been reported that CSCs can 
survive ionizing radiation induced cell killing, by activation of DNA damage response 
(79), by having an extended G2 phase of the cell cycle which allows more efficient 
DNA repair (25), or by their high ability to scavenge reactive oxygen species (82). 
Based on these findings, it has been speculated that CSCs might be responsible of 
tumor recurrence after therapy.  
The CSCs niche 
Similar to their normal counterparts, CSC reside in specific niches within the tumor, 
that can regulate their self-renewal and differentiation abilities (83). Dynamic 
interaction between CSCs and their stromal partners has been reported in several 
cancers, and was found to contribute to the behavior of CSCs (84).  In gliomas, CSCs 
were found to be chemoattracted to endothelial cells nearby to reside in a perivascular 
niche, and their tumorigenic ability was found to be enhanced by co-transplantation of 
endothelial cells (85). Perivascular CSC niche was also described at the invading front 
of OSCC, and co-culture with endothelial cells was shown to enhance survival and 
self-renewal of CSCs (86). In breast (87) and colon (88) cancers, CSC niche was 
observed at the invading front of the tumor, in close proximity to stromal cells that 
promote the invasion process.  
Methods used for CSCs identification 
Research in CSCs has inherited several functional methods that have been employed to 
identify normal stem cells. Firstly, long term retention of DNA analogues like, 
Bromodeoxyuridine, has been used to localize normal stem cells. This phenomena was 
first attributed to their slow cycling rate (89), and more recently to the observation that 
stem cells selectively segregate newly replicated DNA to the daughter cells (68). 
Nevertheless, employing the methods in a cancer investigation would underestimate 
the frequency of CSCs by missing the ones at a high proliferative state. Secondly, 
normal keratinocytes grown in vitro have been classified into stem cells, early and late 
29
TAs according to their pattern of clonal expansion. In culture, the three subpopulations 
have been able to form holoclones, meroclones and paraclones respectively. Their 
ability to express certain molecules previously related to stemness, and to grow on 
further passages was found to be in accordance with the anticipated proliferative 
capabilities of the three cell types (90). Thirdly, sphere formation assay is based on the 
ability of stem cells to self-renew and differentiate independent of anchorage (91). 
Fourthly, differentiation ability of stem cells is investigated in vivo by transplantation 
into immunodeficient mice (9). When transplanted into immunodeficient mice, a CSC 
is presumed to recapitulate the heterogeneity of the original tumor it was derived from. 
Therefore, serial transplantation in animal models, also known as in vivo
tumorigenicity assay, is regarded as the gold standard functional assay to identify a 
CSC subpopulation in a tumor (52).  
Identification of distinctive markers for CSCs is considered a fundamental evidence 
for the existence of CSC in a particular tumor (64). Attempts to isolate CSC are often 
made by the use of fluorescent activated cell sorting (FACS) based on marker 
expression, prior to subjecting them to further functional assays (54, 55). The hunt for 
robust markers for CSCs in many tumors is still commencing, with the suggested ones 
resulting in a variable reproducibility and impurity (50, 52, 64, 92). Technically, the 
need to sort out viable cells has limited the selection of potential markers to the ones 
on the cell surface, like CD44, CD24(56) and CD133 (93). Exceptions of this are the 
isolation of cells according to their ability to expulse DNA binding dye Hoechst 33342 
from their nucleus, and the activity of aldehyde dehydrogenases. Isolation of  stem 
cells by flow cytometry as the side population (SP) that excludes Hoechst 33342 (94), 
is based on the expression of ATP Binding Cassette family (ABCs), which is a family 
of transmembrane proteins known to function as pumps to efflux toxic materials from 
inside the cell. Among other ABCs, the subgroup G2 (ABCG2 or BCRP1) is known to 
be expressed by stem cells (69). On the other hand, Aldehyde dehydrogenases 
(ALDH) are a family of intracellular detoxifying enzymes. There are at least 13 
members of aldehyde dehydrogenases family in humans, classified into three classes. 
Their functions include detoxification of intracellular toxins, and metabolizing retinol 
during embryogenesis (95, 96). High activity of the isoform ALDH1A1 has been 
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suggested as a characteristic of both normal and cancer stem cells in the human colon 
(97) and breast (98), and has been suggested as a universal stem cell marker in many 
normal tissues and cancer types (99, 100). Aldehyde dehydrogenase-based cell 
detection assay has been developed and is commercially available as a kit 
[ ALDEFLUORTM, STEMCELL technologies, Grenoble, France] (101, 102). This 
assay is based on a fluorescent, non-toxic substrate for ALDH1 that can diffuse freely 
into viable cells. In the presence of ALDH1, the utilized substrate is retained inside the 
cell, and the amount of fluorescent signal produced is proportional to the ALDH1 
activity. This assay has been used for enrichment of normal and malignant 
hematopoietic stem cells (103, 104).  
The CSCs phenotype in OSCC 
As in many other solid tumors, the above mentioned methods have been employed for 
isolation of CSCs in OSCC, to further investigate their characteristic surface markers. 
Primary head and neck squamous cell carcinoma cells separated for CD44 expression 
and subsequent transplantation into NOD\SCID mice showed significantly higher 
tumorigenicity of CD44High cells, as compared to CD44Low cells (105). Tumors formed 
by CD44High cells were found to recapitulate heterogeneity of the original tumors, with 
respect to histology and to the expression of CD44. Additionally, 
Immunohistochemistry (IHC) showed high expression of BMI1 in CD44+ cells. 
Although less incident, it is worth mentioning here that transplantation of CD44Low
cells at large numbers have resulted in tumor formation in the same study (105). This 
finding was attributed to low numbers of CSCs within CD44Low subpopulation, and the 
authors reported CD44High subpopulation to be enriched in CSCs. In subsequent 
studies, ALDEFLUORTM assay was found to identify a subpopulation of OSCC with 
CSC properties and CD44High cells represented 50- 70% of that subpopulation (101). 
Transplantation into NOD\SCID mice revealed a tumor formation incidence of 24/25 
and 3/37 for ALDH1br and ALDH1di OSCC cells respectively (106). Another study 
reported that ALDH1br OSCC cells are undergoing EMT, and that knock down of 
Snail resulted in reducing their tumorigenicity (107). Enhanced radiosensitivity and 
decreased tumorigenicity of  ALDH1br OSCC cells by knock down of BMI1 was also 
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reported (108).  In addition, ALDH1+ cells were found to be present at the invading 
front of OSCC and that they co-express CD44 and matrix metalloproteinase -9 (106).  
The dye exclusion method yielded a SP of OSCC that displayed higher colony 
formation, drug resistance and differentiation abilities in vitro, and tumorigenicity in 
vivo, as compared to non-SP (109, 110). Interestingly, SP of OSCC was also found to 
express higher levels of CD44 (105). Others investigators (111) focused on analyzing 
the spheres formed by OSCC cells, and found high expression levels of CD133, a 
putative CSC marker in brain cancer (58), that was previously found to be highly 
expressed by CD44High OSCC cells (112). Subpopulation of CD133+ cells in OSCC 
was also found to display CSC properties and to be more resistant to chemotherapy 
(113). However, holoclones formed by OSCC cells, in another study, were found to 
exhibit weak CD133 by IHC (114), and in vivo tumorigenicity of CD133+ OSCC cells 
has not yet been tested. 
1.2.3 Recent views on tumor heterogeneity 
The  latest perspective views heterogeneity of a population of cancer cells as a 
multifactorial process, in which clonal evolution, different microenvironmental 
conditions and cancer cell plasticity play a role in a tumor that might, or might not 
have a hierarchical organization (50). In the latter case, differences due to epigenetic 
modifications are only secondary to differences exerted by clonal evolution, and CSCs 
would arise stochastically from any of the neoplastic cells within a tumor (64). This 
prospective is supported by the failure, in some cancer types, to identify a pure CSC 
population and to reproduce or generalize the findings in other patients with the same 
tumor type (50, 64, 92). Findings from experimental work have also shown that CSC, 
in some tumors, may arise stochastically (76, 115, 116), and therefore, are considered 
a dynamic cell state rather than an individual cell type (117). 
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2. Rationale of the study 
To date, none of the previously reported markers seem to specify a pure CSC 
subpopulation of OSCC cells. Expression of high ALDH1 levels was found to select a 
subpopulation of OSCC cells that exhibited stem cell behavior, and expressed high 
levels of CD44 (101). The same study found ALDH1di subpopulation to infrequently 
form tumors. This indicated that a more specific phenotypic signature is needed to 
isolate a pure CSC subpopulation from OSCC, and it was speculated that the 
combination of several markers might be necessary for yielding a pure CSC 
subpopulation (92). 
Given the notion that CSCs may originate from their normal counterparts, the normal 
keratinocyte stem cell marker p75NTR comprises a putative CSC marker in OSCCs 
(5). High expression of p75NTR was found to correlate with poor prognosis in patients 
with OSCC (45). In esophageal squamous cell carcinoma, p75NTR was found to 
identify a self-renewing, chemotherapy resistant subpopulation (118), but it is not 
known if this is the case in OSCC or how this correlates with the ALDH1 activity. 
In addition, recent reports have shown that the CSCs subpopulation is a rather dynamic 
compartment (115, 117, 119, 120). This have added more complexity to the model, 
and added variability over time as an additional factor (50). CSCs have been shown in 
OSCC to switch between two phenotypes, but the plasticity between non-CSC and 
CSCs in cancers in general and OSCC in particular is still a controversial issue and far 
from being elucidated.  
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3. Aims of the study 
General aim 
To investigate the pattern of expression of the normal oral keratinocyte stem cell 
marker p75NTR, and the CSC-related marker ALDH1A1, and their co-localization 
during OSCC progression from NHOM. 
Specific aims 
1- To establish a method for simultaneous immunohistochemical detection of 
several CSC-related markers (Paper I). 
2- To identify the pattern of expression of p75NTR and ALDH1A1, relative to 
each other, during progression of OSCC from normal mucosa (Paper II).  
3- To investigate the clinical significance of p75NTR, ALDH1A1 expression and 
their co-localization in OSCC patients (Paper II). 
4- To investigate p75NTR as a putative CSC marker in OSCC (Paper III). 
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4. Methodological considerations  
In the current work, a combination of both in vitro and in vivo experimental data and 
in vivo descriptive data from patient material was generated (Figure 8). Collection of 
samples and isolation of cells for use in this project were approved by the regional 
Medical Ethical Committee for West and North Norway. The use of in vitro assays has 
been criticized in some branches of the biomedical sciences (121). The method of 
isolation followed by grafting in foreign environment was found, for example, to 
induce changes in gene expression profile of beta cells isolated from pancreas (122, 
123), and fundamental behavioral changes were considered a cell culture artifact 
(124). Although provided with the basic nutrients and growth factors, monolayer 
submerged cultures lack the dynamic conditions, the interaction with other types of 
cells and the tissue architecture found in vivo (125-128). However, in vitro assays have 
major advantages compared to in vivo assays in addition to being more feasible and 
less technically and financially demanding, like the wide array of commercially 
available kits and reagents, as well as the flexibility conferred to carry out various 
experimental designs to answer specific hypothesis. Therefore, the use of in vitro stem 
cell assays is advocated given certain conditions (52). Careful discussion and 
interpretation of our data indicated consistency between the two types of methods for 
the key findings of the present study.  
Details of the methods employed are described in the respective papers attached to this 
thesis. Briefly, a protocol for triple IHC was established (Paper I), and expression of 
p75NTR and ALDH1A1, and their co-localization with BMI1 (CSC-related markers) 
was investigated in NHOM, OD and OSCC formalin fixed paraffin embedded samples 
(whole OSCC biopsies and tumor cores constructed in TMA) (Paper II) by use of the 
method developed in paper I. Frequency of positive cells and co-localization of the 
three CSC-related markers was scored semi-quantitatively, dichotomized, compared 
between the three types of samples, and investigated for clinical significance in OSCC 
patients. Subsequently, anti-BMI1 antibody was replaced by anti-Ki67 antibody in a 
similar triple IHC protocol. Percentage of Ki-67 positive cells within p75NTR+, 
ALDH1A1+ and p75NTR+ALDH1A1+ was determined and compared to each other, as 
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well as across the three types of samples (Figure 8A). Comparison between the 
expression levels of CSC-related markers was also compared between the tumor center 
and invading front, using triple IHC as well as qRT-PCR in laser microdissected 
pieces from FFPE OSCC samples (Figure 8A).  
To investigate the expression of CSC-related markers in OSCC derived cell lines 
(Paper II), a panel of cell lines derived from NHOM, OD and OSCC were grown in the 
appropriate type of medium under standard culture conditions. Cells were 
simultaneously investigated by FACS for ALDH1 activity using ALDEFLUORTM
assay, p75NTR expression using a two-layered immunostaining and CD44 using a 
directly conjugated antibody (Figure 8B). Although ALDEFLUOR assay employs a 
specific inhibitor to ALDH1A1 as a negative control, the substrate was found to react 
to other isoforms of ALDH1 (129). Therefore, cells sorted using this method will be 
referred to, throughout the thesis, as ALDH1br/di for bright and dim respectively.  
To investigate the stem cell properties of p75NTRHigh cells (Paper III), p75NTRHigh and 
p75NTRLow CaLH3 cells were sorted out using FACS, and collected in FAD medium. 
Both subpopulations were used for in vivo and in vitro stem cell assays, cell cycle 
analysis, drug resistance and quantitative RT-PCR (Figure 8B).  
To investigate the change in expression of p75NTR and ALDH1 over time (Paper II & 
III), the sorted subpopulations were propagated in culture for a week, and the FACS 
analysis was performed once more. Xenografts formed by injection of the two 
subpopulations were subjected to immunohistochemistry for p75NTR, Ki-67 and 
involucrin (Figure 8B, green arrows).  
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Figure 8: Flow chart of the methods used in the project. 
4.1 The use of formalin fixed archival tissues (Paper I & II) 
Fixation of tissues in cross-linking fixatives involves structural changes in the tissue 
proteins, and may have adverse effects on subsequent immunohistochemical reactions 
(130-132). The samples used in this study where archival formalin fixed/paraffin 
embedded tissues, with no available information about the duration of fixation (Paper I 
& II). To control for false negative samples, an internal positive control have been 
employed for each of the targeted antigens. These were lymphocytes for BMI1 and 
ALDH1A1, and nerve tissues for p75NTR. Repeated lack of a detectable 
immunoreactivity of any of the internal controls would result in exclusion of the 
sample from further analysis (Figure 9). To control for unspecific binding, one tissue 
section was assigned as a negative control, in which incubation with primary antibody 
was omitted and a non-binding negative control mouse IgG1 (DAKO, Golstrup, 
Denmark) was used instead. Additionally, endogenous enzyme activity was quenched 
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using the appropriate substrate, and blocking with normal serum equivalent to the 
secondary antibody was performed on every experiment.  
Figure 9: FFPE samples from OSCC immunostained for BMI1 (brown nuclear color). 
Immunoreactivity observed both in the tumor cells and the tumor stroma (lymphocytes and fibroblasts) 
(A). Lack of distinct reaction in the stroma (B) resulted in exclusion of the sample. 
4.2 The choice of primary antibodies and triple IHC (Paper I & 
II) 
The anti-ALDH1A1 antibody used for IHC in this project (BD Biosciences, New 
Jeresy, USA, 1:250) was previously found to identify a subpopulation of 
ALDEFLUOR positive cells and none of the ALDEFLUOR negative cells (98). The 
choice of anti-BMI1 antibody was also based on previous publications [Merk 
Millipore, Massachusetts, USA (12, 109, 133, 134)]. For optimization of the IHC 
protocol, samples from human testis and cervical lymph nodes were used as positive 
controls, and the two antibodies were tested individually (135). In our hands, anti-
BMI1 antibody was found to show a specific IHC nuclear reaction with good intensity 
when epitope retrieval was performed by heating the sections to 125 ࡈC in Target 
Retrieval Buffer (pH 6.0, Dako), using a pressure cooker (Decloaking ChamberTM , 
Biocare Medical, California, USA). The adequate dilution range for each of the two 
antibodies was determined accordingly. The anti-p75NTR antibody (Sigma-Aldrich, 
St. Louis, USA) (136), used for both FACS and IHC in paper III, gave the best signal 
38
to noise ratio by performing enzyme induced epitope retrieval as recommended by the 
manufacturer. To overcome this problem in our proposed triple staining, another 
monoclonal mouse anti-p75NTR antibody (Millipore) (5, 118, 137), that works with 
the same retrieval method as the other two antibodies was tested and subsequently 
adopted for triple IHC. In addition, mouse monoclonal anti-Ki67 (Dako) was included 
in the investigation. 
Based on these choices, the next challenge was to combine three unconjugated mouse 
antibodies from the subclass IgG1 in a triple IHC protocol. Triple staining was 
conducted sequentially, and the reactions were detected using the following methods: 
i) labeled polymer-horseradish peroxidase conjugated to goat anti-mouse 
immunoglobulins (LP-HRP, EnVision+ ®, Dako). ii) Mixture of biotinylated goat 
anti-mouse and anti-rabbit immunoglobulins (REAL LINK ®, Dako), followed by 
streptavidin conjugated to horseradish peroxidase (REAL Streptavidin Peroxidase®, 
Dako). iii) Dextran polymer coupled with secondary antibodies against mouse and 
rabbit immunoglobulins (Link rabbit/mouse®, Dako), followed by labeled polymer-
alkaline phosphatse anti-mouse/rabbit (LP-AP, Dako). Incubation with secondary 
immunoreagents was performed according to manufacturer`s instructions. 
Chromogens used were 3,3`-diaminobenzidine tetrahydrochloride (DAB), Permanent 
Red (both from Dako), ImmPACT SG and ImmPACT VIP (both from Vectorlabs, 
California, USA), resulting in grey, purple and red colors respectively.  
Different approaches were tested to prevent cross-reactivity between subsequent 
reactions. Firstly, the shielding effect of DAB was investigated using different 
dilutions for the respective primary antibody as reported before (138). Secondly, a 
commercially available blocking solution that is a part of the EnVision ™ G|2 
Doublestain System (Dako), was tested for triple staining, with or without a saturation 
step using a non-binding Negative Control Mouse IgG1 (139). Thirdly, the use of 
microwave heating for denaturation of antibodies from preceding reaction was also 
investigated as previously reported (140, 141). The order of the reactions and 
chromogens assigned to them was based on the antigens subcellular localization, the 
resulting signal intensity, shielding effect of the chromogens and their ability to 
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withstand denaturation steps. The experiments were performed as illustrated in Figure 
10.   
Figure 10: Flow chart illustrating the IHC protocol and the sequence of primary antibodies (Source: 
Paper I). 
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4.3 Evaluation of IHC, visual vs. digital (Paper I, II & III) 
Visual evaluation of the immunostaining was performed by one observer after 
calibration of IHC scores with two co-workers. The scoring systems employed were 
based on the literature (Table 1), and calibration was performed on triple stained 
sections. For patient material (Paper II), the observer had no prior knowledge of the 
clinical information of the patients. For the xenografts (Paper III), the slide labels were 
covered until the evaluation process is finished.  
score BMI1(142) p75NTR (143) ALDH1A1 (144) 
0 <1 % <1 % <5 % 
1 1-25 % 1-25 % 5-25 % 
2 26-50 % 26-50 % 25-50 % 
3 >50 % >50 % >50 % 
Table 1: Semi-quantitative IHC scoring of CSC-related markers. 
Digital image analysis is commonly used for immunofluorescence, and only rarely for 
bright field microscopy (145). Visual evaluation of tissue sections subjected to 
multiple immunoenzyme staining requires careful selection of chromogens, and the 
color products have to be well contrasting to the human eye (131, 145). The task is 
more challenging when co-localization of the reactions products is of interest, then the 
mixture of the chromogens at the site of co-localization should have a distinct color 
(131, 145). Nowadays, several systems for evaluation of immunoenzymatically stained 
slides are available, the technologies used by different systems were reviewed by 
Mulrane et al (146). In this project, ScanScope ® system was employed in paper I to 
validate the usefulness of the combination of colors used. While in paper III, the 
method was used to compare the intensity of involucrin staining between the two 
xenografts groups (Figure 11).  
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Figure 11: Xenograft model stained for Involucrin (brown)(A), the markup image generated by the 
color deconvolution algorithm, intensity of the staining is reflected by yellow to red color, blue 
represents negative structures (B). 
4.4 Cell lines and culture conditions (Paper II & III) 
A panel of cell lines was used in this study. Oral squamous cell carcinoma derived cell 
lines: CaLH3, 5PT, Neo (known as PE-CA/PJ15) (147), primary OSCC cells LuC4 
(148), and oral dysplasia derived cell lines: DOK, Poe9n (149) and D20 (150). Normal 
keratinocytes were isolated from gingival NHOM donated by four patients undergoing 
wisdom tooth extraction at Haukeland University Hospital after informed consent. All 
OSCC cell lines and primary cells were grown in DMEM medium  supplemented with 
25% nutrient mixture F-12 Ham, 50 μg/ml L ascorbic acid, 0.4 μg/ml hydrocortisone, 
10 ng/ml epithelial growth factor (all from Sigma-Aldrich, St. Louis, MO, USA), 10% 
fetal bovine serum (FBS) and 5 μg/ml insulin (both from Life technologies, CA, 
USA), also known as FAD medium (126).while normal keratinocytes and Poen9 were 
grown in Keratinocytes serum free medium (KSFM), supplemented with 10 ng/ml 
epithelial growth factor and 25 μg/mL bovine pituitary extract (Life technologies). All 
cells were grown under standard culture conditions.  
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4.5 FACS analysis and controls (Paper I & III) 
All FACS procedures were performed in BD FACSAriaTM IIu (BD Biosciences, NJ, 
USA). Separation of cells for p75NTR (1:250, Sigma) expression was based on the 
threshold detected by incubating part of the sample with a negative control mouse 
IgG1(Dako) instead of the primary antibody. Secondary antibody used was Alexa 
Fluor® 488 F(ab1)2 fragment of goat anti-mouse H+L (1:250, Life technologies), and 
emitted fluorescent signal was read using 525/50 BP filter.  
Similar approach was followed when cells were separated for ALDH1 activity using 
ALDEFLUORTM assay. Part of the sample was incubated with DEBAB to inhibit 
ALDH1 activity, according to the manufacturer`s instructions. Postsort checking was 
performed after each of the sorting sessions. The error detected by post-sort check 
comprised 1-2%, and may be attributed to loss of the fluorescent signal of the 
secondary antibody, or effluxing the ALDEFLUOR reagent from inside the cells 
during the FACS procedure. In general, the purity of the sorted subpopulations seemed 
to be related to the length of the sorting session.  
Same negative controls were employed for detecting the frequency and overlap 
between p75NTR, ALDH1 and CD44 subpopulations simultaneously. In those 
experiments, secondary antibody used to detect p75NTR reaction was conjugated to 
AF 647, which has a different emission wave length from ALDEFLUORTM, while 
CD44 was detected using PE-mouse antihuman CD44 (BD biosciences 1:1000). This 
has enabled reading the emitted signals through different filters as illustrated in figure 
12. 
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Figure 11 : Illustration of the difference in excitation, emission and filters used for ALDEFLUORTM
assay (A), PE (B) and AlexaFluor® 647 (C). Source: BD spectrum viewer 
(http://www.bdbiosciences.com/research/multicolor/spectrum_viewer/) 
4.6 The choice of the animal model (Paper III)  
The animal experiments were approved by the Norwegian Animal Research Authority, 
transplantation of the tumor cells was conducted under anesthesia (Figure 13), and 
none of the mice needed to be euthanized before the end of the experiment. 
It is considered that in vivo tumorigenicity assay must be performed in the most 
possible permissive conditions, so as to avoid underestimation of the cells with a 
tumor formation potential (50). Adhesion molecules and growth factors essential for 
the growth of the transplanted human cells might not be available in the new 
microenvironment (151, 152). In this project, transplantation of cells was done 
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orthotopically, the OSCC cells being injected into the tongue of mice. The advantage 
of this was reported to mimic the original microenvironment of the OSCC cells, 
offering a more normalized conditions than in other sites (153). Additionally, cells 
were suspended in reduced growth factors Matrigel (BDbiosciences) to provide them 
with a matrix that would help for tumor growth. 
The effect of the animal`s immunity on the transplanted human cells would also hinder 
determination of all the tumorigenic cells evident (154, 155). The animal model used 
in this project was NOD\SCID IL2Rܶnull mice, also known as NSG, which lacks 
natural killer cells, T and B-cells and have defective macrophages and dendritic cells 
(156). Being one of the most immunodeficient available strains, NSG mice comprise a 
relatively permissive environment as compared to NOD\SCID mice that have retained 
their natural killer cell activity (50, 157). It was reported that unselected melanoma 
cells are more likely to form tumors in NSG mice compared to NOD/SCID (116). On 
the other hand, a role of macrophages in promoting invasion of gastric cancer cells 
was shown (158). In that senesce, the model might be less permissive for studying 
metastasis. Ideally, generation of immunocompetent autochthonous models for human 
OSCC would comprise a better model (155, 157). 
Figure 13: Transplantation of OSCC-derived cells into the tongue of the mouse under anaesthesia (A). 
Appearance of the tumor, weeks later, on the inferior surface of the tongue (B) 
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4.7 Laser microdissection of FFPE OSCCs  
Sections of 15 micron thickness of FFPE OSCCs were placed on membrane coated 
glass slides (MembraneSlide NF 1.0 PEN, Zeiss, Oberkochen, Germany), after 
activating the membrane with UV light for 30 minutes. Slides were then incubated at 
56 °C for 2 hours, de-paraffinized in xylene for 4 minutes, rehydrated in graded 
ethanol, stained with methylene green (Dako), and dehydrated in reverse graded 
ethanol and xylene. Fifty to hundred μm2 tissue specimens from the tumor center and 
the corresponding invading front of each OSCC sample were laser microdissected 
(Figure 14) using a Zeiss Axiovert 200 inverted microscope equipped with a 
microlaser system (P.A.L.M Microlaser Technologies). Microdissected tissues were 
collected in nuclease free tubes (AdhesiveCap, Zeiss) and subjected to RNA extraction 
using RNeasy FFPE Kit (Qiagen, Limburg, Netherlands). 
Figure 14 : P.A.L.M microlaser equipment with membrane slide and adhesive cap in place (A), screen 
shots of the area selected for microdissection (green line) (B), and after microdissecting and 
catapulting the selected area (C). The catapulted piece in the adhesive cap as photographed under the 
light microscope (black arrow) (D).  
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4.8 Statistical analysis 
Analysis of qRT-PCR data (Paper II & III) was performed in GraphPad Prism 6 
(GraphPad, CA, USA), while all other statistical procedures were conducted in 
Statistical Package for Social Sciences (SPSS), version 19 (IBM, NY, USA). 
Immunohistochemistry scores have been dichotomized and dealt with as a categorical 
variables, correlation to clinical parameters was therefore investigated using Chi-
Square test and fissure exact test as appropriate. Comparison of IHC scores between 
different areas of the same sample was performed by using McNemar test. For 
continuous variables, the choice of parametric Vs non-parametric statistical tests was 
based on exploring the normality of the distributions using Shapiro-Wilk`s test. 
Survival analysis was performed using Kaplan-Meier`s analysis, and possible 
confounding factors were investigated using Cox proportional hazard models. The 
level of significance was set to 0.05, results are presented as (mean ± SD) for 
continuous variables and statistical tests used are mentioned in their respective parts in 
the thesis. 
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5. Results 
5.1 Successful triple IHC protocol for simultaneous detection of 
CSC-related markers (Paper I) 
Consistent with a previous report (145), shielding effect of DAB was found to be 
dependent on the dilution of the respective primary antibodies. In our experiments, 
high dilution of primary antibodies whose reactions were visualized with DAB 
resulted in a mixed color when subsequent reaction was performed directly afterwards, 
while low dilutions resulted in less immunoreactivity of neighboring antigens (picture 
not shown). Sections subjected to triple IHC by employing a blocking step showed 
cross reactivity, and spurious color was evident despite the use of different detection 
systems (Figure 15).  
Figure 15: Section from FFPE sample of cervical lymph node subjected to triple IHC protocol 
employing a blocking step, BMI1 (brown), p75NTR (purple), ALDH1A1 (red), arrow head indicates a 
mixed color at the cell membrane (A). Similar section subjected to triple IHC protocol employing a 
denaturation step, BMI1 (brown), p75NTR (purple), ALDH1A1 (gray), no cross reaction observed.  
Comparing sections subjected to triple IHC protocol employing a denaturation step to 
the ones subjected to single staining, showed a consistent staining pattern for each of 
the reactions. Furthermore, specificity of each of the three reactions was evident when 
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negative control mouse IgG was used to replace one of the primary antibodies at a 
time (Figure 16). The three reactions were found consistent with the expected types of 
cells and the subcellular compartment, despite the use of the same secondary 
immunoreagent for all reactions.  
Figure 16: sample from human testis subjected for triple IHC with denaturation steps, BMI1 (brown), 
p75NTR (purple), ALDH1A1 (gray) (A),sections from  same sample subjected to the same IHC 
protocol, but one of the antibodies was replaced  with a non-binding mouse IgG1 (B-D). 
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The colors produced by the three reactions were found distinguishable even in cells 
where the three antigens were co-expressed, as evident by digital image analysis 
(Figure 17). These data show that the denaturation IHC protocol reported here is 
reliable for simultaneous detection of three antigens located in different subcellular 
compartments.    
Figure 17:Human cervical lymph node sample subjected to triple IHC protocol involving denaturation 
steps (A). Markup images for each of the reactions as generated by the algorithm (B-D). 
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5.2 Triple IHC revealed higher frequency and wider distribution 
of the expression of CSC-related markers in OSCC and OD 
compared to normal mucosa (Paper II) 
5.2.1 Simultaneous expression of CSC-related markers by cells of the basal 
layer in NHOM 
Triple IHC identified the three CSC-related markers in 23 (74.2 %) of the NHOM 
samples included in the study. Eight (25.8 %) samples were found to be negative for 
ALDH1A1. 
Expression of p7NTR was identified as a membranous staining of groups of the basal 
layer cells, at the tips of both the rete ridges and the connective tissue papillae (Figure 
18). Accordingly, the percentage of p75NTR+ cells was found to be consistently low, 
but present in all NHOM samples (Figure 19A).  
Figure 18: Representative example of NHOM subjected to triple IHC for CSC-related markers, BMI1 
(brown), p75NTR (purple), ALDH1A1 (grey). Triple positive cells detected within the basal layer (A,B 
arrows). ALDH1A1 positive cells distributed in vertical patches (C,D) 
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Immunoreactivity for ALDH1A1 was detected as cytoplasmic with or without nuclear 
staining. Most of NHOM samples (67.7%, N= 21) scored 0-5% ALDH1A1+ cells 
(Figure 18A,B). Keratinocytes positive for ALDH1A1 were located at both the basal 
and spinous cell layers. A particular distribution of ALDH1A1+ cells was found in the 
two samples scoring 25-50% ALDH1A1+, involving vertical patches /clones of 
keratinocytes from the basal layer till superficial layers (Figure 18C,D, Figure 19B). 
Nuclear staining for BMI1 was detected both in the basal and spinous layers of the 
epithelium in all NHOM samples (Figure 18), and high frequency of positive cells 
(>50%) was detected in 8 samples (25.8%) (Figure 19C). 
The overlap between p75NTR+ and BMI1+ cell populations was evident within the 
basal layer cells in all 31 samples. Rare cells co-expressing the three CSC-related 
markers were found in the basal layer compartment of 20 samples (64.5 %).  
Figure 19: Scores of IHC for p75NTR (A), ALDH1A1  (B) and BMI1 (C) in the three types of samples. 
5.2.2 Increased scatterness of the frequencies of the three cell populations 
in OD compared with NHOM 
70% of the OD samples had low frequency of p75NTR positive cells (Figure 19A).  
Expression of p75NTR by 25-50% of the cells was detected in two samples, including 
some of spinous cell layer cells. One sample showed no p75NTR+ cells, despite the 
immunoreactivity of the nerve tissues in the section. The same observation was made 
for ALDH1A1, and >50% positive cells were detected in two samples (Figure 20E), 
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and no ALDH1A1 cells were detected in two others (Figure 19B). In all 10 OD 
samples, BMI1+ cells comprised more than 50% of the epithelial cells in the section.  
Figure 20:Representative examples of ODs stained for CSC related markers (A-F), BMI1 (brown), 
p75NTR (purple), ALDH1A1 (gray). 
A statistically significant increase in the number of cells positive for each of the CSC-
related markers was found in ODs as compared to NHOMs (Chi-Square test, Figure 
21). 
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Figure 21:Scatter plots showing comparison of the dichotomized IHC scores for p75NTR (A), 
ALDH1A1 (B) and BMI1 (C), between the three types of samples.  
In addition, the clone like distribution of ALDH1A1+ cells was more frequently 
detected (30%) among OD samples (Figure 20A,B). Co-localization of p75NTR or 
ALDH1A1 with BMI1 was detected in all samples expressing the two markers (n= 8 
and 9 respectively). However, half of the OD samples were lacking the overlap of 
p75NTR+ and ALDH1A1+ populations (Figure 22). 
Figure 22: Detection of co-localization of CSC-related markers in the three types of samples.\ 
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5.2.3 Higher and increased heterogeneity in the expression of CSC-related 
markers in OSCC compared to NHOM and OD 
Triple IHC revealed that 15.8% (n= 28) of OSCC samples expressed p75NTR by 
>50% of the tumor cells, with p75NTR+ cells detected in multiple layers (Figure 23). 
On the other hand, 28.8% (n= 51) had <1% p75NTR+ cells. Expression of ALDH1A1 
by >50% of the cells was detected in 16.9% (n=30) of OSCC samples (Figure 19). 
Cells positive for ALDH1A1+ were detected both at the peripheries of the invading 
islands, and at the more differentiated central areas (Figure 23). Expression of BMI1 
was also variable, with 59.9% (n=106) of the samples scoring three, and 7.3% (n=10) 
scoring 0. For all of the three CSC-related markers, disparity of the expression was 
observed even between different areas within the same OSCC sample (Figure 23). 
Figure 23: Representative example of an OSCC sample stained for CSC-related markers, same colors 
as figure 18.  
With the exception of BMI1, statistical significance was achieved when the 
dichotomized IHC scores for CSC-related samples in OSCC were compared to NHOM 
(Chi-Square), but not when compared to ODs (Figure 21). 
Of the OSCC samples included in this study, 35.03% (n= 62) included a para-tumor 
epithelium. The clone like distribution of ALDH1A1+ cells was detected in 56.6% of 
these samples (Figure 24). 
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Figure 24: Representative example of para-tumor epithelium from the edge of an OSCC stained for 
CSC-related markers, BMI1 (brown), p75NTR (purple), ALDH1A1 (grey). Picture shows high 
expression of ALDH1A1 at the para-tumor epithelium.  
5.2.4 OSCC samples that contained cells positive for the three CSC-related 
markers were rare 
It is noteworthy here that five (2.8 %) OSCC samples showed no expression of any of 
the three markers by the tumor cells, despite the positivity of the internal controls, and 
that only 37.9% (n= 67) OSCC samples scored more than 0 for p75NTR and 
ALDH1A1 simultaneously. Co-localization of p75NTR or ALDH1A1 with BMI1 was 
detected in 58.2% (n= 103) and 52.5% (n= 93) respectively. Cells positive for both 
p75NTR and ALDH1A1 were detected only in 19.2% (n= 16) of all OSCC samples, 
and triple positive cells were detected in 18.1% of the samples (n=32) (Figure 22).  
5.2.5 No difference between the tumor center and invading front or lymph 
nodes metastasis in the expression of the three CSC-related markers 
Scores obtained from IHC for the three CSC-related markers from the tumor center 
were compared to tumor invading front (n=25) or metastatic lymph node tumors 
(n=19) as pairs (Figure 25A-D). No statistically significant difference was observed 
for any of the three markers investigated (Table 2, McNemar test).  
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  Tumor center 
  Low High Total p-value
  ALDH1A1 
   
   
   
 In
va
di
ng
 fr
on
t ALDH1A1 Low 19 (100%) 5 (100%) 24 (100%) ND 
High 0 0 0   
p75NTR 
p75NTR Low 
15 (88.2%) 6 (85.7%) 21 (87.5%) 0.289 
High 2 (11.8%) 1 (14.3%) 3 (12.5%)   
BMI1 
BMI1 Low 
5 (100%) 5 (26.3%) 10 (41.7%) 0.074 
High 0 (0.0%) 14 (73.7%) 14 (58.3%)   
  ALDH1A1 
Ly
m
ph
 n
od
e 
m
et
as
ta
sis
 
ALDH1A1 Low 
13 (100%) 3 (50.0%) 16 (84.2%) 0.248 
High 0 (0%) 3 (50.0%) 3 (15.8%)   
p75NTR 
p75NTR Low 
13 (86.7%) 1 (25.0%) 14 (73.7%) 1.000 
High 2 (13.3%) 3 (75.0%) 5(26.3%)   
BMI1 
BMI1 Low 
3 (75.0%) 5 (33.3%) 8 (42.1%) 0.221 
High 1 (25.0.3%) 10 (66.7%) 9 (57.9%)   
Table 2: Comparison of the dichotomized IHC scores from three CSC-related markers, between the 
tumor center and invading front or lymph nodes metastasis, using McNemar test.  
The expression levels of mRNA for p75NTR and ALDH1A1 was compared between 
laser micro-dissected pieces from the tumor center and tumor invading front in 23 
OSCC samples. No reaction product was detected in some of the samples, and the 
pair-wise comparison was valid only in seven samples for ALDH1A1, and eight for 
p75NTR. No statistically significant difference was found (Figure 25E).  
Although based on a small number of cases, these data indicated that the expression of 
the CSC-related markers investigated in this study was similar at the tumor center, 
invading front and lymph node metastasis. 
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Figure 25: Representative two samples from OSCC subjected to triple IHC of CSC-related markers 
(A-D), BMI1 (brown), p75NTR (purple) and ALDH1A1 (grey). Pictures taken from tumor center (left) 
and lymph node metastasis (right). Bar chart comparing relative expression of p75NTR and 
ALDH1A1 in the tumor center and invading front (E). Error bars represents standard deviation. 
5.2.6 Lack of co-localization and heterogeneously increased expression of 
CSC-related markers in in vitro OD and OSCC-derived cells 
A step-wise increase in the expression of p75NTR at the protein level was found to 
follow the disease progression from NHOM, through OD to OSCC, despite the lack of 
p75NTR+ cells in some OSCC samples. A similar change in the expression of 
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ALDH1A1 and CD44 was observed, although OD samples showed slightly higher 
expression levels. For all three CSC-related markers, the expression level was found to 
display wider ranges in OSCC and OD-derived cells when compared to NOKs (Figure 
26 A-C, Table 3). However, these findings were found not be statistically significant 
(Kruscal-Wallis test). 
Figure 26: Area-under-the curve chart showing the expression levels, and frequency of co-localization 
of CSC-related markers in NOKs (n=4), OD (n=3) and OSCC (n=4) -derived cells. 
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  p75NTR+ ALDH1+ CD44+ 
NOK113 2.70 ± 0.00 6.57 ± 0.12 4.40 ±  0.78 
NOK109 2.93 ± 0.23 7.03 ± 0.40 3.97 ± 0.25 
NOK108 1.2 ± ND 3.4 ± ND 3.7 ± ND 
NOK105 2.5 ± ND 5.2 ± ND 4.7 ± ND 
Poei9n 8.5 ± ND 8.4 ± ND 5.1 ± ND 
D20 5.7 ± 0.00 14.8 ± 0.14 14.45 ± 0.49 
DOK 0.75 ± 0.07 3.35 ± 0.07 5.1 ± 0.14 
5PT 5.3 ± 0.53 3.23 ± 0.06 3.17 ± 0.21 
CaLH3 29.13 ± 0.55 9.7 ± 0.17 14.67 ± 0.49 
LuC4 0.25 ± 0.07 3.85 ± 0.07 10.15 ± 0.21 
Neo 0.7 ± ND 0 ± ND 4.4 ± ND 
Table 3: Frequency of the three subpopulations (mean ± SD) in cells derived from NHOM (top), OD 
(middle) and OSCC (bottom) as examined by FACS analysis. 
On the other hand, co-localization of pairs, or all the three of the CSC-related markers, 
was found to be more variable as the disease is progressing from normal to OSCC 
(Figure 26D-H, Table 4).  
  p75NTR+ALDH1+ p75NTR+CD44+ CD44+ALDH1+ p75NTR+ALDH1+CD44+
NOK113 Ϭ͘ϭϲцϬ͘Ϭϭ Ϭ͘ϯϳцϬ͘ϬϮ ϯ͘ϱϵцϬ͘Ϭϰ Ϭ͘ϭϰцϬ͘Ϭϭ
NOK109 Ϭ͘ϮϱцϬ͘Ϭϰ Ϭ͘ϰϭцϬ͘Ϭϯ Ϯ͘ϭϯцϬ͘Ϯϭ Ϭ͘ϭϮцϬ͘ϬϮ
NOK108 Ϭ͘ϬϮцE Ϭ͘ϬϳцE Ϯ͘ϬϳцE Ϭ͘ϬϭцE
NOK105 Ϭ͘ϭϰцE Ϭ͘ϱϲцE Ϯ͘ϭϬцE Ϭ͘ϭϰцE
Poei9n Ϭ͘ϴϯцE ϭ͘ϱϰцE ϭ͘ϬϰцE Ϭ͘ϮϴцE
D20 Ϭ͘ϵϳцϬ͘ϭϬ ϭ͘ϴϮцϬ͘ϯϴ ϲ͘ϲϴцϬ͘ϭϲ Ϭ͘ϳϰцϬ͘Ϭϱ
DOK Ϭ͘ϬϯцϬ͘ϬϬ Ϭ͘ϭϳцϬ͘ϬϮ Ϭ͘ϮϵцϬ͘Ϭϲ Ϭ͘ϬϭцϬ͘ϬϬ
5PT Ϭ͘ϮϯцϬ͘Ϭϯ Ϭ͘ϰϱцϬ͘Ϭϰ Ϭ͘ϱϯцϬ͘Ϭϲ Ϭ͘ϬϳцϬ͘Ϭϭ
CaLH3 Ϯ͘ϬϯцϬ͘Ϭϴ ϴ͘ϮϱцϬ͘ϰϬ ϳ͘ϰϮцϬ͘Ϯϰ ϭ͘ϴϴцϬ͘ϭϬ
LuC4 Ϭ͘ϬϭцϬ͘Ϭϭ Ϭ͘ϬϯцϬ͘Ϭϭ Ϭ͘ϬϵцϬ͘Ϭϭ Ϭ͘ϬϬцϬ͘ϬϬ
Neo ϬцE Ϭ͘ϮϯцE ϬцE ϬцE
Table 3: Frequency of co-localization (mean ± SD) of the three subpopulations in cells derived from 
NHOM (top), OD (middle) and OSCC (bottom) as examined by FACS analysis. 
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5.2.7 Increased proliferation in p75NTR+ OSCC cells compared to ALDH1 
Comparison of the mean percentages of proliferating cells within p75NTR+, 
ALDH1A1+ and p75NTR+ALDH1A1+ cell subpopulations was performed for 
NHOM (n=19) and OSCC samples (n= 58) (Figure 27A,B). Friedman test revealed a 
significant difference between the percentages of proliferating cells in the three cell 
subpopulations in NHOM (P-value= 0.006) as well as in OSCC (P-value= 0.000), and 
a higher percentage of proliferating cells was observed in p75NTR+ subpopulation. 
Further comparison of pairs of the three cell subpopulations using Wilcoxon-Rank test 
(Figure 27C,D) revealed a significant difference between p75NTR+ and ALDH1A1+ 
in NHOM (P-value= 0.005) and OSCC (P-value= 0.000). Another statistically 
significant difference was found between p75NTR+ and p75NTR+ALDH1A1+ 
subpopulations in NHOM (P-value= 0.008) and in OSCC (P-value= 0.000), but not 
between ALDH1A1+ and p75NTR+ALDH1A1+ subpopulations neither in NHOM (P-
value= 0.217) nor in OSCC (P-value= 0.273). 
Figure 27: Representative examples from NHOM (A) and OSCC (B) subjected to triple IHC for 
p75NTR (brown), ALDH1A1 (purple) and Ki-67 (gray). Bar charts comparing the frequency of 
proliferating cells in the three subpopulations in OSCC (B) and NHOM (C).
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5.2.8 High expression of p75NTR and ALDH1A1 in OSCC correlated with 
different clinical parameters 
High expression of p75NTR was found to be associated with small size tumors, and 
tumors graded as low-moderately differentiated (0.034 for both, Chi-Square test). 
Kaplan-Meier`s curve showed that patients with high p75NTR expressing tumors are 
more likely to survive shorter within a period of 10 years (Figure 28A), but the finding 
was not statistically significant (Tarone-Ware test). Stratifying the same analysis by 
tumor size revealed a similar difference in the survival probabilities in patients with 
T1-T2 tumors, but not in patients with T3-T4 tumors (Figure 28B,C).  
Figure 28: Kaplan-Meier`s curves showing the difference in survival probabilities between between 
OSCCs with high or low frequency of p75NTR+ cells. The analysis was conducted for all cases (A), 
for T1 & T2 (B) and T3 & T4(C) OSCCs. 
Despite the lack of statistical significance, Cox regression hazard models revealed 
similar survival pattern, and a marked change in the hazard ratio was observed when 
the analysis was adjusted by the tumor size (Table 4). 
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Model Overall sig. covariate Co-efficient (B) Sig. Exp(B) HR 
Crude 0.247 p75NTR - 0.213 0.248 0.808 1.24 
Splitting data by Tumor size 
T1 & T2 0.088 p75NTR - 0.418 0.09 0.658 ϭ͘ϱϮ
T3 & T4 0.966 p75NTR - 0.015 0.966 1.015 1.03 
Adjusted for tumor size  0 p75NTR - 0.4 0.104 0.67 1.49 
  Tumor size 0.087 0.091 1.796 1.796 
    Interaction 0.862 0.403 1.407 1.407 
Table 4: Cox regression hazard models containing p75NTR as the only co-variate (Top), when the 
data were split by tumor size (middle) and when p75NTR, Tumor size and their interaction variable as 
co-variates.  
On the other hand, high ALDH1A1 expression was found to be associated with lymph 
nodes metastasis (0.035, Chi-Square test). These data show that p75NTR and 
ALDH1A1 expression affect different aspects of the disease progression at different 
stages of the disease. 
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5.3 p75NTRHigh OSCC-derived cells displayed several 
characteristics previously related to the CSC-phenotype (Paper 
III) 
Cells sorted according to p75NTR expression were subjected to different CSC assays. The 
percentage of p75NTRHigh cells that formed spheres or colonies (Figure 29) were found to be 
4.14% ± 1.28 and 44% ± 2.58 respectively, compared to only 1.7% ± 0.58 and 25.3% ± 3.4 
for p75NTRLow cells. These data show that higher percentage of the seeded p75NTRHigh 
CaLH3 cells formed colonies and spheres with a statistically significant difference, as 
compared to p75NTRLow cells (p= 0.000, Mann-Whitney test). 
Figure 29: Representative images of colony (upper) and sphere (lower) formation assays for 
p785NTRHigh (left) and p75NTRLow (right) CaLH3 cells. 
The incidence of tumor formation was found to be higher in mice injected with p75NTRHigh 
cells than in mice injected with p75NTRLow cells (90%, 70% respectively). The highest 
difference in tumor formation incidence was observed at the first reading (70% for 
p75NTRHigh compared to 30% for p75NTRLow ). Pair wise comparison of the mean tumor size 
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between the two animal groups at each of the time points, showed that tumors generated by 
p75NTRHigh cells were growing significantly bigger (P-value = 0.043, Wilcoxon Signed Rank 
Test). However, IHC for Ki-67 showed no difference in the percentage of proliferating cells 
between the two animal groups. Instead, a difference in the expression of involucrin was 
detected by digital image analysis of sections subjected to IHC for that differentiation marker. 
These data show a shorter lag phase and higher growth rate of xenografts (Figure 30) 
generated by p75NTRHigh cells at their early stages.   
Figure 30: Representative images of xenograft models generated by transplantation of p75NTRLow (A) 
and p75NTRHigh CaLH3 cells into NSG mouse tongue. 
Additionally, cell cycle analysis (Figure 31) showed that a higher proportion of p75NTRHigh
cells (32.07% ± 9.2) were found to be at G2 phase compared to p75NTRLow (8.91% ± 3.34) 
and the unsorted CaLH3 population (22.15% ± 9.02) . The p75NTRHigh cells were also found 
to be more resistant to 5-Fluorouracil than p75NTRLow cells as evident by the drug resistance 
experiment.  
Figure 31: Bar chart displaying cell cycle distribution of CaLH3 cells sorted for p75NTR expression 
or not. Error bars represents standard deviation. 
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5.4 Subpopulations of p75NTRHigh and ALDHbr cells displayed 
different expression profile of CSC and EMT related molecules 
(Paper II) 
Both p75NTRHigh and ALDH1br were found to have higher expression of surface markers 
previously related to CSCs in OSCC, as compared to their negative counterparts by qRT-
PCR. Nonetheless, the gene POU5F1 was found to be higher expressed by ALDH1di cells as 
compared to ALDH1br cells, while inverse pattern was detected in cells sorted for p75NTR 
expression. The EMT marker vimentin was found to be upregulated in ALDH1br cells but not 
in p75NTRHigh cells. Additionally, expression pattern of differentiation markers (CK-13 and 
involucrin) indicated that ALDH1br cells are more differentiated than their negative 
counterpart (Figure 32).   
Figure 32: Bar Charts representing relative mRNA expression levels of CSC and EMT related 
markers (left) and differentiation markers (right), for cells sorted for p75NTR (A,B) or ALDH1 (C,D) 
expression. 
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5.5 Subpopulations of p75NTRHigh and ALDH1br OSCC-derived 
cells could spontaneously arise from a more differentiated 
subpopulation (Paper II) 
Cells sorted for p75NTR or ALDH1 expression were propagated in culture for a week, 
and the FACS analysis was performed as before. Based on the concomitant negative 
control, cells propagated from p75NTRHigh were found to contain 40.1% p75NTRLow 
cells. While 8.06% p75NTRHigh were detected within cells propagated from 
p75NTRLow.  
Similar observation was made when xenografts generated from p75NTRLow CaLH3 
cells were compared to the ones generated from p75NTRHigh cells, and IHC showed no 
difference in the number of p75NTR+ cells. 
Propagation of cells sorted for ALDH1 activity for the same period of time as for 
p75NTRHigh cells, showed that cells propagated from ALDH1br included 97.73 
ALDH1di. On the other hand, 0.17% ALDH1br were found to arise from propagation of 
ALDH1di cells. These data show that p75NTRHigh and ALDH1br OSCC-derived cells 
can arise de novo spontaneously in culture (Figure 33). 
Figure 33: Bar chart displaying postsort checking and percentage of positive cells arising de nove 
after propagation in culture.  
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6. Discussion 
6.1 Variability in the expression of CSC-related markers in 
patients with OD and OSCC as compared to NHOM 
Variability in the expression of CSC-related markers has been previously reported and 
high expression levels have been correlated to patients prognosis in melanoma (159), 
colorectal (57) and breast cancers (160), glioma (161) and OSCC (111). In AML, the 
frequency of ALDH1+ cells was found to vary from 1-16% (104). Another study found 
that CD34+CD38- varied by 1000 folds in a cohort of 16 patients (162). In OSCC 
primary cells, CD44+ cells varied from 0.1% to 41.72%  (105). Another study found 
an increase in the expression of several CSC-related markers in OSCC-derived cell 
lines in comparison to ones derived from OD or NHOM (149). Nevertheless, 
correlation between the degree of this variability and the progression of disease has not 
been addressed so far. In this project, expression of p75NTR and ALDH1A1 in OD 
and OSCC was found to be increased in comparison to NHOM, and high expression 
was found to be associated with poor prognosis and less survival chances of OSCC 
patients, which is in agreement with previous reports.  However, the widely scattered 
level of expression of all three CSC related markers observed in OD and OSCC as 
compared to NHOM is one of the key new findings. Cells positive for p75NTR, for 
example, comprised more than 50% in some OSCCs, a high frequency that was not 
detected in any of the NHOM samples, while other OSCCs contained <1%  p75NTR+ 
cells. The distribution of cells positive for CSC-related markers was also found to be 
heterogeneous in OSCC and OD as compared in NHOM. In fact, loss of spatial 
regulation of CD44 and p75NTR was reported before in an OSCC in vitro 3D model, 
but not in parallel stepwise models constructed for NOKs or OD-derived cells (149). 
This variability in expression and distribution may be due to differences in the genetic 
background of the disease and/or in the tumor microenvironment.  The lack of 
expression of all three CSC-related markers observed in some of OSCC in this study 
(n= 5), indicates that progression of these tumors is driven by another phenotype that 
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does not oblige BMI1 involvement. Perhaps these tumors are not hierarchically 
organized and all.  
6.2 Multiple CSC subpopulations 
Investigations on CSC from different models often yielded variable findings. In AML, 
leukemic stem cells were first identified as CD34+CD38-  (54, 55). Other studies have 
reported CD34- subpopulation to contain leukemic stem cells (163, 164). Additionally, 
CD34+ALDH1br subpopulation was also found to enrich in leukemic stem cells (104) 
as well as in the side population (165, 166). The same can be concluded for some solid 
tumors. In breast cancer, CSC have been descried as expressing CD44+CD24- (56). 
Later on, CSC activity was detected within the ALDH1 and this subpopulation was 
found to have only 1% overlapping with CD44+ subpopulation (98).  In melanoma, 
CSC were first identified as p75NTR+ (167) but later on CSC have been identified 
within p75NTR- subpopulation (168). In OSCC, CSCs were first identified by use of 
CD44 (105), then ALDH1 bright subpopulation was also found to exhibit stem cell 
properties and to overlap with CD44high subpopulation (101). Such inconsistencies 
between studies on the same tumor type can be due to difference in the experimental 
conditions, with underestimation of phenotypes that are potentially tumorigenic 
resulting from non-permissive experimental conditions. These conditions include the 
xenogenic immune barrier, as well as differences in the microenvironment (50). 
Another point of view attributes such difference in the phenotype of the tumorigenic 
cells to differences in the genetic background, cell of origin, site of tumor, histological 
subtype, microenvironment and time point [reviewed (50, 92, 154)]. However, it has 
been shown in pancreatic cancer, that there might be more than one CSC 
subpopulation within the same tumor (169). In this project, we found that p75NTRHigh
cells displayed more CSC properties than the p75NTRLow cells. However, p75NTRLow
cells also seemed to contain few cells with CSC properties. In addition, our data 
showed that the overlap between p75NTR and ALDH1A1 is a rare finding both in 
patient materials and OSCC cells, and these two subpopulations seemed to be two 
separate subpopulations, minimally intersecting. This was also supported by 
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performing qRT-PCR on sorted CaLH3 cells, where p75NTRLow cells were found to 
express higher levels of ALDH1A1 as compared to p75NTRHigh cells, and vice versa.  
Phenotypical differences between CSCs often reflected functional differences in many 
models. In inflammatory breast cancer, ALDH1+ CSCs were correlated to metastasis 
while CD44+CD24- CSCs were found to be highly proliferative (160). Similar 
observations were made in OSCC (119), where CD44highESAhigh cells were found to 
comprise the proliferative compartment, while CD44highESAlow were the EMT 
compartment. In pancreatic adenocarcinoma, only CD133+CXCR4+ cells comprised 
the metastatic phenotype, and not the rest of CD133+ cells (169). Even normal 
hematopoietic stem cells have been classified into long term self-renewing, short-term 
self-renewing and multipotent progenitors without detectable self-renewal potential 
organized respectively in a hierarchy (63). In our samples, multiple IHC has showed 
that p75NTR+ cells were more proliferative than ALDH1A1+ cells, and 
p75NTR+ALDH1A1+ cells. This finding was in line with the suggested proliferation 
promoting role of p75NTR in mouse embryonic stem cells (29). We also found 
p75NTR expression to be correlated with less survival chances in patients with small 
size tumors. In addition, OSCC cells with high p75NTR expression exhibited higher 
resistance to 5-Fluorouracil as compared to p75NTRLow subpopulation. On the other 
hand, ALDH1br cells were found to express higher levels of the EMT-related marker 
vimentin. High expression for ALDH1A1 was also found to be associated with 
occurrence of lymph node metastasis. This is in line with previous studies showing a 
role of ALDH1+ OSCC cells in invasion (119), and reported the presence of those 
cells at the tumor invading front (106). In the current project, no difference in the 
expression level of ALDH1A1 or p75NTR between the tumor center and the invading 
front was observed. This can be due to the small sample size available for analysis. 
Although further functional investigation is needed, we theorize that these two 
subpopulations have different functions. 
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6.3 A role for cancer cell plasticity in de novo emergence of 
p7NTRhigh and ALDH1br cells 
Our data showed that p75NTR+ and ALDH1+ cells could arise de novo in culture 
from a generally more differentiated subpopulation, and we described this 
phenomenon to occur also in vivo for p75NTR high cells. A possible explanation of this 
can be that these cells arise from another rare CSC population lurking within the 
negative compartment. In OSCC, CSCs were previously shown to have the ability to 
switch between two CSC phenotypes, an epithelial one and an EMT one positive for 
ALDH1 (119). In the present study, only partial overlap was found between 
p75NTR+, ALDH1+ and CD44+. This shows that a subpopulation that is negative for 
one of the three markers would contain cells positive for the two other markers. We 
have not investigated the generation of, for example, p75NTR+ cells from 
CD44+p75NTR- cells, and therefore, this explanation remains to be proven. Another 
explanation would be by the generation of p75NTR+ or ALDH1+ cells from the more 
differentiated, non-CSC, negative progeny by undergoing de-differentiation. This was 
shown in breast cancer, and mathematical modelling indicated that CSCs could arise 
stochastically from more differentiated breast cancer subpopulations (115). In fact, 
induction of de-differentiation of adult somatic cells into a pluripotent stem cell has 
already been performed (9), but under the influence of defined factors and the process 
was thought to involve reversion of epigenetic modifications (170).  
Although we described de novo alteration of the phenotype that we observed both in 
culture and in vivo as ‘spontaneous’, one might argue that those conditions were stress 
conditions since selecting for only one phenotype of cells might have disturbed the 
equilibrium that might exist in a tumor at a certain point between multiple, 
phenotypically diverse cell subpopulations.   It has been argued that cells with CSC 
properties may arise as result of high plasticity of the tumor cells in response to signals 
from the tumor microenvironment. Therefore, hypothetically it has been argued that 
any cell in a tumor can display CSC properties (50). Mathematical modelling showed 
also that tumorigenic behavior is a rather probabilistic potential of all tumor cells 
(171), and using a very permissive mouse model, it was found that any cell in some 
71
melanomas can be a CSC (116). It was also suggested that tumor growth of melanoma 
is dependent on a temporary distinct subpopulation that is generated by turning on and 
off a histone demethylase (172). Subpopulations with therapy resistance were also 
suggested to arise reversibly from drug sensitive cells (173). Our data revealed a 
statistically significant association between high p75NTR and small size tumors. We 
interpreted that the p75NTR activity might be required in small size tumors but turned 
off/ not of importance later in some patients. The need for multiple methods for 
identification/isolation of CSC  
Given the variability of the CSC phenotype between patients with the same tumor 
type, multiplex methods for simultaneous detection of potential CSC markers are 
needed. Such methods might comprise a useful tool for investigation of the 
relationship between CSC markers identified in different reports in individual patients. 
In the future, such methods might be feasible for classifying patients for individualized 
cancer therapy. In the current study, we optimized a method for combining antibodies 
from same subclass, which is often an obstacle for researchers. Multiple IHC have the 
advantage of utilizing patient materials without the need to expose the cells to 
enforceable events during culture. In addition, it provides long lasting histological and 
topographical details. Sections subjected to this protocol were found analyzable using 
digital image analysis, which can make evaluation of a large number of samples less 
laborious to researchers.  
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7. Conclusions 
7.1 Multiple IHC reported here was found useful to investigate the relationship 
between different subpopulations with potential CSC properties, and can be applied for 
the same purpose in other types of cancer. 
7.2 Different patients with OSCC have different CSC-related marker profile. 
Expression of p75NTR and ALDH1A1 is apparently related to different aspects of 
OSCC progression.  
7.3 Plasticity may play a role in generation of OSCC cells with CSC properties. 
p75NTR was found to identify a subpopulation of OSCC cells in a transient stem cell 
state. This subpopulation is more proliferative than ALDH1A1 and highly enriched in 
small size tumors.  
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8. Future perspectives 
8.1 Comparison of p75NTRHigh and ALDH1br OSCC cells from different cell lines and 
primary OSCC cells, in terms of proliferation, invasion, drug resistance, 
tumorigenicity and plasticity. 
8.2 Investigation of the CSC properties of p75NTRHighALDH1br cells. 
8.3 Exploring the expression pattern of a wider spectrum of potential CSC markers 
simultaneously in larger sample size of patient material. 
8.4 Applying the mathematical model reported before in Breast cancer (115), to 
investigate the fate, relationship and source of p75NTRHighALDH1di, 
p75NTRLowALDH1br , p75NTRHighALDH1br, p75NTRLowALDH1di. 
8.5 Propagation of cells sorted for CSC-related marker with conditioned medium 
collected from the total population of the same cells, and observing the change in the 
regeneration of CSCs by cells in the negative compartment. 
8.6 Gene expression profiling of the dye retaining OSCC cells. 
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